Mutations in genes responsible for histone and chromatin modifications, such as CREBBP, KMT2D, EZH2, and TET2, drive aberrant epigenetic B cell programming and influence DLBCL clinical outcome [53]. The gene discussed is CREBBP; the disease is diffuse large B-cell lymphoma.